VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$945.53$97.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksREGNBalance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Balance Sheet

30Y historyFree accessUpdated daily

Leverage remains minimal, with total debt flat near $2.7B and debt-to-equity of 0.08 in 2026Q3, while the current ratio compressed from 5.44 to 3.35, still indicating a comfortable liquidity cushion.

Income StatementBalance SheetCash FlowRatios

REGN Balance Sheet

Annual statement

REGN Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets20.8B18.02B18.66B19.48B15.88B14.01B9.78B7.69B7.96B5.6B3.91B3.38B2.51B2.25B1.62B913.59M720.05M425.51M521.44M797.83M469.98M341.39M343.95M320.21M276.95M394.19M134.14M73M92.9M99.6M85M
Cash & Short-Term Investments9.3B8.61B9.01B10.84B7.74B5.69B3.59B3.21B2.81B1.41B1.04B1.05B900.48M693.98M308.1M526.94M249.37M341.33M474.75M766.46M459.28M298.55M295.98M293.77M264.27M385.08M117.61M66.2M19.8M28.9M34.5M
Cash Only3.66B3.12B2.49B2.73B3.11B2.89B2.19B1.62B1.47B812.73M535.2M809.1M648.72M535.61M230.28M483.61M112.57M207.07M247.8M498.93M237.88M184.51M101.23M118.28M80.08M247.39M30.98M23.7M19.8M28.9M34.5M
Short-Term Investments5.64B5.49B6.52B8.11B4.64B2.81B1.39B1.6B1.34B596.85M503.48M236.12M251.76M158.38M77.82M43.33M136.8M134.25M226.95M267.53M221.4M114.04M194.75M175.49M184.19M137.69M86.63M42.5M000
Accounts Receivable7.58B5.74B6.21B5.67B5.33B6.04B4.11B2.79B2.24B1.97B1.61B1.47B976.37M954.97M693.12M103.03M81.92M65.57M35.21M18.32M7.49M36.52M43.1M15.53M4.02M2.98M13.84M600K5.7M6.6M4.3M
Days Sales Outstanding138.34146.1159.65157.7159.78137.09176.75155.05122.01122.72121.03130.55126.39165.61183.5384.3665.1363.153.953.4843.11201.3890.4198.5866.6849.4285.196.3554.4672.7865.12
Inventory2.89B3.2B3.09B2.58B2.4B1.95B1.92B1.42B1.15B726.14M399.36M238.58M128.86M70.35M28.64M13.56M-15.14M00002.9M3.23M9.01M6.83M3.97M1.92M4.6M000
Days Inventory Outstanding466.22556.14571.87419.64514.13261.49515.98529.69721.6488.53360.41186.22182.51130.6486.11140.18-----42.37.79492.39384.59222.7944.9466.39---
Other Current Assets0474.8M349.2M386.6M00000000044.68M148.13M0000000000001.6M67.4M64.1M46.2M
Total Non-Current Assets23.61B22.54B19.1B13.6B13.33B11.42B7.38B7.12B5.29B4.43B3.79B2.69B1.75B1.15B874.48M657.81M731.81M315.69M202.78M138.43M115.11M82.11M129.15M159.35M114.63M101.21M74.13M64M64M68.8M52.6M
Property, Plant & Equipment5.73B5.12B4.6B4.15B3.76B3.48B3.22B2.89B2.58B2.36B2.08B1.59B974.31M526.98M379.94M367.95M347.45M259.68M87.85M58.3M49.35M60.53M71.24M80.72M76.83M39.45M36.93M36.3M33M32.7M34.3M
Fixed Asset Turnover3.13x2.80x3.09x3.16x3.23x4.62x2.64x2.27x2.61x2.49x2.33x2.57x2.89x3.99x3.63x1.21x1.32x1.46x2.71x2.14x1.29x1.09x2.44x0.71x0.29x0.56x1.60x0.95x1.16x1.01x0.70x
Goodwill0000000000000000000000000000000
Intangible Assets1.32B1.26B1.15B1.04B915.5M6.7M0000000000000000000000000
Long-Term Investments39.43B10.26B8.9B5.4B6.59B6.84B3.14B3.26B1.75B1.49B864.26M632.16M460.15M389.89M271.23M275.89M370.05M47.08M51.06M000000000000
Other Non-Current Assets2.47B1.82B1.14B444.1M336.4M216.1M168.1M144.7M127.4M77.9M20.29M5.81M3.03M5.33M31.29M13.96M14.31M8.94M9.68M1.9M65.75M21.57M57.91M78.63M37.8M61.76M37.2M27.7M31M36.1M18.3M
Total Assets44.41B40.56B37.76B33.08B29.21B25.43B17.16B14.81B11.73B8.76B6.97B5.61B3.87B2.95B2.08B1.32B1.09B741.2M670.04M936.26M585.09M423.5M473.11M479.56M391.57M495.4M208.27M137M156.9M168.4M137.6M
Asset Turnover0.40x0.35x0.38x0.40x0.42x0.63x0.50x0.44x0.57x0.67x0.70x0.73x0.73x0.71x0.66x0.34x0.42x0.51x0.36x0.13x0.11x0.16x0.37x0.12x0.06x0.04x0.28x0.25x0.24x0.20x0.18x
Asset Growth %36%7.41%14.14%13.23%14.86%48.19%15.93%26.17%33.89%25.68%24.32%44.87%31.2%41.84%57.19%21.49%46.98%10.62%-28.43%60.02%38.16%-10.49%-1.34%22.47%-20.96%137.86%52.02%-12.68%-6.83%22.38%46.7%
Total Current Liabilities6.2B4.37B3.94B3.42B3.14B3.93B2.7B2.1B1.44B1.14B1.24B811.16M654.66M298.83M163.55M148.27M109.06M93.58M83.67M283.66M45.01M40.36M34.14M72.92M40.12M22.02M13.79M13.3M9.4M10.7M12M
Accounts Payable1.14B939M789.5M606.6M589.2M564M475.5M418.1M218.2M178.2M134.98M140.96M99.51M61.94M38.93M27.74M15.59M18.64M6.27M8.13M4.35M4.2M4.41M18.93M30.31M14.83M9.45M6.6M5.6M4.7M4.4M
Days Payables Outstanding161.91163.15146.2498.65126.1275.58128.01156.46136.77119.89121.82110.03140.94115.01117.06286.8261.25426.97187.37-69.8161.2110.631.04K1.71K831.61221.49669.17408.8659.811.46K
Short-Term Debt0000000000000000000200M00013.82M150K426K612K1.4M1.1M1.8M3.6M
Deferred Revenue (Current)2.16B553M627.7M458.9M477.9M442M577.7M591.7M452.5M320.14M231.66M153.49M74.03M47M50.83M300.25M54.72M44.54M209.93M44.43M23.54M17.02M15.27M40.17M9.66M6.77M00000
Other Current Liabilities000000085M001.18M13.56M97.15M00012.03M00002.29M000005.3M2.7M4.2M4M
Current Ratio3.35x4.13x4.73x5.69x5.06x3.56x3.63x3.67x5.52x4.93x3.15x4.17x3.83x7.54x9.91x6.16x6.60x4.55x6.23x2.81x10.44x8.46x10.08x4.39x6.90x17.90x9.73x5.49x9.88x9.31x7.08x
Quick Ratio2.89x3.39x3.95x4.94x4.29x3.07x2.91x2.99x4.72x4.29x2.83x3.88x3.63x7.30x9.73x6.07x6.74x4.55x6.23x2.81x10.44x8.39x9.98x4.27x6.73x17.72x9.59x5.14x9.88x9.31x7.08x
Cash Conversion Cycle442.66539.09585.28478.69547.79323564.71528.28706.83491.36359.62206.75167.97181.24152.57-62.27-----182.4687.56-444.16-1.26K-559.4-91.4-196.43---
Total Non-Current Liabilities4.7B4.93B4.46B3.68B3.41B2.73B3.44B1.62B1.53B1.48B1.28B1.14B632.76M700.1M671.55M689.58M452.56M250.87M219.03M192.33M323.45M269.14M256.43M268.99M205.47M207.02M12.36M14.2M16.3M18.8M18.7M
Long-Term Debt1.99B1.99B1.98B1.98B1.98B1.98B1.98B00000146.77M320.31M296.52M275.02M005.09M0200M200M200M200M200M200M1.47M2.7M3.1M3.8M5.1M
Capital Lease Obligations720M720M720M720M720M0717.2M713.9M708.5M703.5M351.57M362.92M310.94M184.26M159.44M159.51M162.18M109.02M0000000150K603K0000
Deferred Tax Liabilities0000000000000000000000000000000
Other Non-Current Liabilities2.5B2.02B1.57B854.1M638M680.2M687.1M799.7M546.6M949.29M100.39M115.53M217.13M11.33M7.26M-247.6M52.57M3.96M00000159K0010.29M11.5M13.2M15M13.6M
Total Liabilities10.91B9.3B8.41B7.11B6.55B6.67B6.14B3.72B2.98B2.62B2.52B1.95B1.33B998.94M835.11M837.85M561.62M344.44M251.19M475.99M368.47M309.5M290.56M341.91M245.59M229.04M26.14M27.5M25.7M29.5M30.7M
Total Debt2.71B2.71B2.7B2.7B2.7B2.7B2.7B713.9M708.5M703.45M481.13M375.51M459.06M505.51M457.33M435.53M160.03M109.02M5.09M202.29M200M200M200M213.82M200.15M200.58M2.68M4.1M4.2M5.6M8.7M
Net Debt-952.1M-412.2M216.2M-27.1M-404.5M-185.9M502M-903.9M-759.2M-109.28M-54.08M-433.59M-189.66M-30.1M227.05M-48.08M47.46M-98.05M-242.7M-296.63M-37.88M15.49M98.77M95.53M120.07M-46.82M-28.3M-19.6M-15.6M-23.3M-25.8M
Debt / Equity0.08x0.09x0.09x0.10x0.12x0.14x0.24x0.06x0.08x0.11x0.11x0.10x0.18x0.26x0.37x0.90x0.30x0.27x0.01x0.44x0.92x1.75x1.10x1.55x1.37x0.75x0.01x0.04x0.03x0.04x0.08x
Debt / EBITDA0.49x0.66x0.60x0.57x0.47x0.29x0.71x0.29x0.26x0.32x0.34x0.28x0.52x0.64x0.92x-------9.52x--------
Net Debt / EBITDA-0.17x-0.10x0.05x-0.01x-0.07x-0.02x0.13x-0.37x-0.28x-0.05x-0.04x-0.33x-0.22x-0.04x0.46x-------4.70x--------
Interest Coverage122.77x120.42x87.59x58.52x82.80x163.75x67.97x81.43x91.55x83.75x185.82x87.03x21.76x16.36x10.15x-9.47x-10.46x-29.79x-9.37x-7.77x-------5.52x---4.03x-1.21x
Total Equity33.5B31.26B29.35B25.97B22.66B18.77B11.03B11.09B8.76B6.14B4.45B3.65B2.54B1.95B1.25B485.73M527.82M396.76M418.85M460.27M216.62M114M182.54M137.64M145.98M266.36M182.13M109.5M131.2M138.9M106.9M
Equity Growth %27.54%6.48%13.02%14.6%20.75%70.23%-0.58%26.63%42.53%38.09%21.74%43.76%30.24%56.74%156.39%-7.97%33.03%-5.27%-9%112.47%90.02%-37.55%32.62%-5.71%-45.19%46.24%66.33%-16.54%-5.54%29.93%57.44%
Book Value per Share317.22287.82255.03228.44199.68167.2895.7996.7776.2853.0138.2631.7222.4117.5410.795.366.364.975.316.943.742.043.252.733.326.335.183.484.234.794.37
Total Shareholders' Equity33.5B31.26B29.35B25.97B22.66B18.77B11.03B11.09B8.76B6.14B4.45B3.65B2.54B1.95B1.25B485.73M527.82M396.76M418.85M460.27M216.62M114M182.54M137.64M145.98M266.36M182.13M109.5M131.2M138.9M106.9M
Common Stock100K100K100K100K100K100K100K100K100K112K110K108K104K99K97K93K89K81K80K79K65K56K56K55K44K44K37K0000
Retained Earnings39.47B35.8B31.67B27.26B23.31B18.97B10.89B7.38B5.25B2.95B1.75B852.7M255.38M-92.69M-517.05M-1.27B-1.05B-941.1M-875.93M-793.22M-687.62M-585.28M-489.83M-531.53M-424.07M-299.7M-223.52M-200.3M-177.2M-168.6M-157M
Treasury Stock-20.95B-18.61B-15.17B-12.56B-10.35B-8.26B-6.61B-739.9M-396.4M-316.24M-316.24M-306.07M-169.53M000000000000000000
Accumulated OCI-197.5M77.5M-7.9M-80.9M-238.8M-26.2M29.3M21.1M-12.3M640K-12.84M8.57M52.25M-1.19M-1.17M-1.86M-2.49M1.04M-114K170K-231K-785K-3.07M-4M-3.17M-1.61M-780K-500K-26.6M-23.6M-5.9M
Minority Interest0000000000000000000000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Revenue lumpiness and buyback-driven cash use

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Compounding Through Retained Earnings

Based on REGN's reported quarterly balance sheets, total equity rose from $28.2B in 2024Q2 to $33.5B in 2026Q3, with retained earnings climbing to $39.5B, a pattern consistent with sustained profit retention over the period.

The steady rise in retained earnings, which grew by roughly $10B across the ten quarters, suggests the company has been converting operating profits into balance sheet strength rather than distributing them. Total assets expanded from $36.1B to $44.4B over the same span, indicating the equity build is translating into a larger asset base rather than being absorbed by liabilities. Investors should monitor whether this retention pace persists given the quarterly volatility in earnings noted in the prior income statement findings.

Minimal Leverage Despite Stable Debt Load

According to reported figures, REGN's total debt held flat near $2.7B across all ten quarters, while the debt-to-equity ratio declined from roughly 0.10 to 0.08, reflecting equity growth outpacing a fixed debt base.

A flat debt balance alongside rising equity means leverage has been diluting passively rather than being actively managed, which suggests the company has had no need to refinance or add borrowings. The very low D/E ratio implies limited financial risk from interest obligations or refinancing windows based on the supplied data. The absence of debt growth does not by itself confirm conservative policy, and the data does not disclose maturity schedules, so refinancing risk cannot be fully assessed from these figures.

Current Ratio Compression Toward Healthy Levels

As reported in financial statements, REGN's current ratio fell from 5.44 in 2024Q2 to 3.35 in 2026Q3, while cash held in a band of roughly $2.0B to $3.7B, leaving a still-comfortable liquidity cushion.

The decline in current ratio reflects growth in current liabilities, which may include deferred revenue and operating obligations, rather than any erosion of current assets. Cash balances remain well above the company's debt, which supports short-term resilience even as the ratio normalizes. The data does not include operating expense detail, so cash runway relative to burn cannot be calculated, and no conclusion about shock absorption beyond the reported ratios is warranted.

Asset-Light Profile With Modest Fixed Capital

Based on REGN's reported figures, net PP&E grew steadily from $4.3B to $5.7B while goodwill remained near $1.1B to $1.4B, suggesting a balance sheet anchored by physical manufacturing capacity rather than acquisition-driven intangibles.

Rising PP&E alongside stable goodwill indicates the company is investing in internal production and research infrastructure instead of growing through acquisitions. This lowers the risk of a large goodwill impairment charge that could distort reported equity. The asset mix is consistent with a biotechnology business whose value rests largely on proprietary products and pipeline rather than on tangible asset intensity.

Deferred Revenue Volatility Limits Forward Read

According to reported quarterly data, deferred revenue swung between $220.4M in 2026Q2 and $970.0M in 2026Q3, indicating that forward-booked revenue is lumpy and offers limited visibility into near-term top-line trajectory.

Deferred revenue appears to be driven by milestone timing and collaboration arrangements rather than recurring subscriptions, which explains the wide quarterly variance. This pattern suggests that a single period's balance is a weak predictor of the next quarter's revenue. Investors should treat the deferred revenue line as a signal requiring context from pipeline and partnership disclosures rather than as a reliable backlog indicator.

Headline Strength Masks Lumpy Underlying Cash Quality

Based on reported figures, the strong equity and low leverage profile may overstate cash resilience, since free cash flow margins swung from 4.0% to 37.8% across quarters and share repurchases often absorbed most of that generation.

A strong balance sheet built on retained earnings can coexist with weak cash conversion when earnings include non-operating items, as the income statement findings already suggest. If buybacks continue at the reported pace, the equity base may grow more slowly than headline retained earnings imply. This warrants further investigation into the quality of reported earnings before treating the balance sheet as a durable buffer.

REGN — Frequently Asked Questions

Quick answers to the most common questions about buying REGN stock.

What are the total assets of Regeneron Pharmaceuticals, Inc. (REGN)?

As of 2025, Regeneron Pharmaceuticals, Inc. (REGN) had total assets of $40.56B including $18.02B in current assets.

How much debt does Regeneron Pharmaceuticals, Inc. (REGN) have?

Regeneron Pharmaceuticals, Inc. (REGN) carries total debt of $2.71B, offset by $8.61B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. (REGN) has total shareholders' equity (book value) of $31.26B ($287.82 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Regeneron Pharmaceuticals, Inc.'s current ratio and liquidity?

Regeneron Pharmaceuticals, Inc. (REGN) reported a current ratio of 4.13x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.